Evidence map›Paper›PMID 39981999›Full record

ArticleParasite (Paris, France)2025

The impact of schistosomiasis on the Global Disease Burden: a systematic analysis based on the 2021 Global Burden of Disease study.

Zhangzhou Shen, Houqiang Luo

Abstract read
In one paragraph

Article in Parasite (Paris, France), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026
    Review
  5. Novel 1ACS infectious diseases · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhangzhou ShenHubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University, Medical School, Huangshi 435003, Hubei, China.ORCID 0000-0002-0946-0922
Houqiang LuoCollege of Animal Science, Wenzhou Vocational College of Science and Technology, Wenzhou 325006, Zhejiang, China.ORCID 0000-0002-2990-6012

Funding

Key Project of Scientific Research Plan of Education Department of Hubei Province, China No. D20224501Kidney Disease Occurrence and Intervention Key Laboratory of Hubei Province Open Fund Project, China No.SB202105Research Project of Hubei Polytechnic University, China No.23xjz09A
6 · The paper itself

Abstract

Schistosomiasis is a neglected tropical disease that causes a significant global burden. The aim of this study was to report the latest estimates of the global, regional, and national schistosomiasis disease burden and forecast changes in schistosomiasis-related disease burden. This work was based on the 2021 Global Burden of Disease (GBD) study. We analyzed the schistosomiasis data by sex, age in years, and Socio-Demographic Index (SDI) region and country, using Age-Standardized Rates (ASR) for comparisons among different groups. The Estimated Annual Percent Changes (EAPC) analysis was used to evaluate the temporal trend of the disease burden, and the Differential Autoregressive Integrated Moving Average (ARIMA) and Exponential Smoothing (ES) models were used to predict the disease burden from 2022 to 2046. In the GBD 2021 study, it was reported that compared to 1990, the number of deaths has decreased by 74,350, the prevalence number has increased by 1,482,260, and Disability-Adjusted Life Years (DALYs) have decreased by 1,770,436. Additionally, the age-standardized mortality rate (ASMR) has decreased by 0.31 per 100,000 people, with an EAPC of -0.353 (95% CI: -0.361 to -0.344). Similarly, the age-standardized DALYs rate (ASDR) has decreased by 15.45 per 100,000 people (EAPC: -1.56, 95% CI: -1.78 to -1.34), and the age-standardized prevalence rate (ASPR) has decreased by 559.64 per 100,000 people (EAPC: -0.63, 95% CI: -0.95 to -0.31). The regions and countries with the highest disease burden are mostly concentrated in Africa. Despite a general decline in global schistosomiasis burden indicators, the burden of disease has actually increased in high SDI areas. The ARIMA and ES models forecast results show that female mortality and ASMR will decline in the next 25 years, while male mortality and ASMR will remain stable, and other disease indicators will continue to decline. The global schistosomiasis burden has significantly decreased over the past 30 years, but it remains high in African regions and countries, as well as low-SDI areas. Effective cooperation among countries should be strengthened to improve the disease burden in high-burden areas and countries.

Indexed as

Global Burden of DiseaseSchistosomiasisAdolescentAdultAgedChildChild, PreschoolCost of IllnessDisability-Adjusted Life YearsFemaleGlobal HealthHumansInfantMaleMiddle AgedNeglected DiseasesAge-standardized ratesEAPCGlobal burdenSchistosomiasis

Identifiers

PMID39981999
PMCPMC11843987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.